title: Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?
authors: Chris O'Brien Lifehouse, Department of Medical Oncology, Camperdown, NSW 2050, Australia.
authors: Michail
authors: M
authors: Charakidis
authors: Chris O'Brien Lifehouse, Department of Medical Oncology, Camperdown, NSW 2050, Australia.
authors: Michael
authors: M
authors: Boyer